Regulatory Approval / Operational Milestone
OneSource Specialty Pharma Receives EU GMP Certification for Sterile Product Division
NSE
onesource
BSE
544292
OneSource Specialty Pharma Limited has received the EU GMP Certificate of Compliance for its Sterile Product Division (SPD) facility in Bangalore from a German regulatory authority, strengthening its global regulatory credentials and enabling access to European markets
PRICE-SENSITIVE TRIGGER
Event:Â Receipt of EU GMP Certification
Type:Â Regulatory Approval / Operational Milestone
Impact: Positive
Immediate Effect:Â Enhances credibility and opens up potential revenue opportunities in regulated European markets, improving long-term growth visibility
What Happened ?
OneSource Specialty Pharma Limited announced that its Sterile Product Division (SPD) facility located in Bangalore has received an EU GMP (Good Manufacturing Practices) Certificate of Compliance.
The certification was granted by the State Office for Occupational Safety, Social Affairs and Health of Schleswig-Holstein, Germany, following an inspection conducted in October 2025.
key highlights
Operational & Regulatory Development:
- Certification received for Sterile Product Division (SPD), Bangalore
- Issued by German regulatory authority (Schleswig-Holstein)
- Certification date: April 27, 2026
- Inspection conducted on: October 14, 2025
- Confirms compliance with EU GMP standards
- Covers sterile products including:
- Small volume liquids (aseptic)
- Secondary packing
- Quality control testing
- Facility capabilities include:
- Liquid vials
- Lyophilized vials
- Pre-filled syringes
- Autoinjectors
- Existing approvals from global regulators: US-FDA, Health Canada, ANVISA, TGA
Note:
EU GMP certification is a critical requirement for exporting pharmaceutical products to European markets and indicates high manufacturing and quality standards.
Risk Analysis
Key Risks
- Delay in converting certification into commercial orders
- Pricing pressure in regulated markets
- Compliance maintenance and periodic inspections
- High competition in sterile injectables segment
Worst Case Scenario
- If the company fails to secure meaningful contracts despite certification, the impact may remain limited to reputational enhancement without financial upside
Risk Level: Medium
Company Commentary
- SPD facility has successfully received EU GMP certification
- Certification validates compliance with stringent EU standards
- Facility is equipped with advanced sterile manufacturing capabilities
- Company continues to strengthen its global regulatory footprint
Official Exchange Filing: OneSource Specialty Pharma Limited